Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK0859-038 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in subjects with impaired renal function and healthy matched control subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1 - Panel A | Experimental | Subjects with severe renal impairment |
|
| Part 1 - Panel B | Experimental | Healthy matched control subjects |
|
| Part 2 - Panel C | Experimental | Subjects with moderate renal impairment |
|
| Part 2 - Panel D | Experimental | Healthy matched control subjects |
|
| Part 2 - Panel E | Experimental | Subjects with mild renal impairment |
|
| Part 2 - Panel F | Experimental | Healthy matched control subjects |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| anacetrapib | Drug | single dose administration of anacetrapib (MK0859) 100 mg oral tablet |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Curve (AUC(0 to infinity)) of anacetrapib | through 168 hours post dose |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events | through 14 days post dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24782116 | Result | Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. J Clin Pharmacol. 2014 Nov;54(11):1247-55. doi: 10.1002/jcph.320. Epub 2014 Jun 6. |
Not provided
Not provided
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| D051437 | Renal Insufficiency |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D007674 | Kidney Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C530884 | anacetrapib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |